Class Action & Mass Torts

Recent Bevou Label Change in Europe Adds Information About Retinal Vasculitis and Retinal Vascular Occlusion   (Posted by Tom Lamb at DrugInjuryWatch.com)   In mid-September 2020 Novartis announced the results of a Phase 3 head-to-head study comparing its relatively new eye medicine Beovu to Eylea, a more well-established competing eye drug product from Regeneron. According to Novartis, this study shows that after one year of treatment Beovu matched Eylea in terms of the best-corrected…
While not authorized by Rule 23, incentive awards to class representatives are a common feature of class action settlements. Nevertheless, a divided Eleventh Circuit panel ruled last Thursday that such payments are strictly prohibited by “on-point Supreme Court precedent” from the 1880s. The decision in Johnson v. NPAS Solutions, LLC, No. 18-12344, 2020 WL 5553312 (11th Cir. Sept. 17, 2020), reversed and vacated a district court order that approved a settlement after the Eleventh Circuit concluded…